Context Therapeutics

Company snapshot

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartere

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Context Therapeutics. Not investment advice.

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  Quantum Pharmaceuticals

  TA overlap score 23.6

• Peer + 0 momentum

  Olema Pharmaceuticals

  TA overlap score 21.4

Recent activity

Latest pipeline, patent, and corporate events for Context Therapeutics.

1. Jun 8, 2026 Clinical update

   Letrozole — Phase 1

2. Jun 8, 2026 Clinical update

   Elacestrant — Phase 2

3. Jun 5, 2026 Clinical update

   Extended-release Onapristone — Phase 2

4. Jun 5, 2026 Clinical update

   CT-95 — Phase 1

5. May 23, 2026 Clinical update

   Onapristone — Phase 2

View all clinical trial activity →

• What is Context Therapeutics?

  Context Therapeutics is a pharma organization headquartered in Philadelphia, USA. It trades on NYSE under ticker CNTX. Primary therapeutic focus areas include Triple Negative Breast Cancer (TNBC), Mesothelin-Expressing Tumors, Platinum-resistant Ovarian Cancer, Breast Cancer, Ref

• Is Context Therapeutics publicly traded?

  Yes. Context Therapeutics is listed with ticker CNTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Context Therapeutics develop or market?

  We link 7 drug profile(s) where Context Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/context-therapeutics#company-drugs.

• What are the latest developments for Context Therapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Context Therapeutics focus on?

  Context Therapeutics focuses on Triple Negative Breast Cancer (TNBC), Mesothelin-Expressing Tumors, Platinum-resistant Ovarian Cancer based on our analysis of their pipeline programs and drug development activities.